These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 30629980)

  • 21. The pathophysiological mechanisms of motivational deficits in Parkinson's disease.
    Chagraoui A; Boukhzar L; Thibaut F; Anouar Y; Maltête D
    Prog Neuropsychopharmacol Biol Psychiatry; 2018 Feb; 81():138-152. PubMed ID: 29097256
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Are dopaminergic pathways involved in theory of mind? A study in Parkinson's disease.
    Péron J; Vicente S; Leray E; Drapier S; Drapier D; Cohen R; Biseul I; Rouaud T; Le Jeune F; Sauleau P; Vérin M
    Neuropsychologia; 2009 Jan; 47(2):406-14. PubMed ID: 18845171
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Depression and impulse control disorders in Parkinson's disease: two sides of the same coin?
    Vriend C; Pattij T; van der Werf YD; Voorn P; Booij J; Rutten S; Berendse HW; van den Heuvel OA
    Neurosci Biobehav Rev; 2014 Jan; 38():60-71. PubMed ID: 24239733
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of the dopaminergic system in mood, motivation and cognition in Parkinson's disease: a double blind randomized placebo-controlled experimental challenge with pramipexole and methylphenidate.
    Drijgers RL; Verhey FR; Tissingh G; van Domburg PH; Aalten P; Leentjens AF
    J Neurol Sci; 2012 Sep; 320(1-2):121-6. PubMed ID: 22824349
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Ophthalmic disorders as a manifestation of Parkinson's disease].
    Chesnokova NB; Pavlenko TA; Ugrumov MV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(9):124-131. PubMed ID: 29053133
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment.
    Chaudhuri KR; Schapira AH
    Lancet Neurol; 2009 May; 8(5):464-74. PubMed ID: 19375664
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A case-controlled study of altered visual art production in Alzheimer's and FTLD.
    Rankin KP; Liu AA; Howard S; Slama H; Hou CE; Shuster K; Miller BL
    Cogn Behav Neurol; 2007 Mar; 20(1):48-61. PubMed ID: 17356345
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Artistic creativity and dementia].
    Sellal F; Musacchio M
    Psychol Neuropsychiatr Vieil; 2008 Mar; 6(1):57-66. PubMed ID: 18364297
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Are we listening to everything the PARK genes are telling us?
    Benson DL; Huntley GW
    J Comp Neurol; 2019 May; 527(9):1527-1540. PubMed ID: 30680728
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enhanced creative thinking under dopaminergic therapy in Parkinson disease.
    Faust-Socher A; Kenett YN; Cohen OS; Hassin-Baer S; Inzelberg R
    Ann Neurol; 2014 Jun; 75(6):935-42. PubMed ID: 24816898
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Conditional deletion of Ndufs4 in dopaminergic neurons promotes Parkinson's disease-like non-motor symptoms without loss of dopamine neurons.
    Choi WS; Kim HW; Tronche F; Palmiter RD; Storm DR; Xia Z
    Sci Rep; 2017 Mar; 7():44989. PubMed ID: 28327638
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The unexplored link between aesthetic perception and creativity: A theory-driven meta-analysis of fMRI studies in the visual domain.
    Sacheli LM; Tomasetig G; Musco MA; Pizzi S; Bottini G; Pizzamiglio L; Paulesu E
    Neurosci Biobehav Rev; 2022 Sep; 140():104768. PubMed ID: 35798126
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Harnessing neurogenesis for the possible treatment of Parkinson's disease.
    Lamm O; Ganz J; Melamed E; Offen D
    J Comp Neurol; 2014 Aug; 522(12):2817-30. PubMed ID: 24723264
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Brain illness and creativity: mechanisms and treatment risks.
    Flaherty AW
    Can J Psychiatry; 2011 Mar; 56(3):132-43. PubMed ID: 21443820
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neuropsychopharmacological aesthetics: A theoretical consideration of pharmacological approaches to causative brain study in aesthetics and art.
    Spee B; Ishizu T; Leder H; Mikuni J; Kawabata H; Pelowski M
    Prog Brain Res; 2018; 237():343-372. PubMed ID: 29779743
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genes, brain dynamics and art: the genetic underpinnings of creativity in dancing, musicality and visual arts.
    Sotiropoulos MG; Anagnostouli M
    J Integr Neurosci; 2021 Dec; 20(4):1095-1104. PubMed ID: 34997732
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PITX3 genotype and risk of dementia in Parkinson's disease: A population-based study.
    Bäckström D; Domellöf ME; Granåsen G; Linder J; Mayans S; Elgh E; Mo SJ; Forsgren L
    J Neurol Sci; 2017 Oct; 381():278-284. PubMed ID: 28991698
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Art produced by a patient with Parkinson's disease.
    Chatterjee A; Hamilton RH; Amorapanth PX
    Behav Neurol; 2006; 17(2):105-8. PubMed ID: 16873921
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reward processing in health and Parkinson's disease: neural organization and reorganization.
    Goerendt IK; Lawrence AD; Brooks DJ
    Cereb Cortex; 2004 Jan; 14(1):73-80. PubMed ID: 14654458
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Motor loop dysfunction causes impaired cognitive sequencing in patients suffering from Parkinson's disease.
    Schönberger AR; Hagelweide K; Pelzer EA; Fink GR; Schubotz RI
    Neuropsychologia; 2015 Oct; 77():409-20. PubMed ID: 26382750
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.